Trading Report: The Amarin Corp. PLC (AMRN) Expected to Earn FY2016 Earnings of ($0.29) Per Share

The Amarin Corp. PLC (AMRN) Expected to Earn FY2016 Earnings of ($0.29) Per Share

Amarin Corp. PLC (NASDAQ:AMRN) – Analysts at Cantor Fitzgerald issued their FY2016 earnings estimates for Amarin Corp. PLC in a report issued on Monday. Cantor Fitzgerald analyst C. Russo expects that the firm will earn ($0.29) per share for the year. Cantor Fitzgerald has a “Buy” rating and a $6.00 price target on the stock. Cantor Fitzgerald also issued estimates for Amarin Corp. PLC’s FY2017 earnings at ($0.14) EPS.

Amarin Corp. PLC (NASDAQ:AMRN) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. The firm earned $32.82 million during the quarter, compared to analyst estimates of $29.97 million. During the same period in the previous year, the firm posted ($0.15) EPS. The company’s revenue for the quarter was up 85.4% compared to the same quarter last year.

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Amarin Corp. PLC in a report on Monday, August 8th. Jefferies Group reiterated a “buy” rating and set a $3.50 target price on shares of Amarin Corp. PLC in a report on Thursday, July 7th. Finally, Zacks Investment Research upgraded Amarin Corp. PLC from a “sell” rating to a “hold” rating in a report on Wednesday, July 6th.

Amarin Corp. PLC (NASDAQ:AMRN) opened at 2.99 on Wednesday. The firm’s market cap is $551.81 million. The company has a 50-day moving average of $2.99 and a 200 day moving average of $2.36. Amarin Corp. PLC has a 52 week low of $1.24 and a 52 week high of $3.46.

Hedge funds have recently added to or reduced their stakes in the stock. Timber Hill LLC raised its stake in Amarin Corp. PLC by 229.8% in the second quarter. Timber Hill LLC now owns 53,504 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 37,283 shares in the last quarter. KCG Holdings Inc. raised its stake in Amarin Corp. PLC by 1.2% in the second quarter. KCG Holdings Inc. now owns 73,026 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 900 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Amarin Corp. PLC during the second quarter valued at about $210,000. State Street Corp raised its stake in Amarin Corp. PLC by 2.4% in the second quarter. State Street Corp now owns 104,259 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 2,491 shares in the last quarter. Finally, ProShare Advisors LLC raised its stake in Amarin Corp. PLC by 0.9% in the second quarter. ProShare Advisors LLC now owns 132,338 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 1,180 shares in the last quarter. Hedge funds and other institutional investors own 20.74% of the company’s stock.

Amarin Corp. PLC Company Profile

Related posts

Leave a Comment